Skip to main content
TrendingNews.today
World News
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
As of Mar 25
ScienceUnited States1 sourcesNeutral

With improved technologies, biomarkers, failed drugs may come into their own

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to move toward success – both at the level of individual companies and for indications as a whole.

AB
anette breindl
via Bioworld
ShareRead original

Read the full article at Bioworld →

With improved technologies, biomarkers, failed drugs may come into their own

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Bioworld
Bioworld
NewsDataUS

Comments

0 comments
Be respectful and constructive.
Loading comments...
Previous
What time is Senate vote today on shutdown 2026? Next vote, DHS news
Next
Iran War: Is the New Zealand economy cooked?

Related Articles

This pinot noir hasn’t changed in 500 yearsScience
This pinot noir hasn’t changed in 500 years
Popular Science-13h ago-1 sources
Gilead pens dual-purpose $2B Ouro M&A deal with GalapagosScience
Gilead pens dual-purpose $2B Ouro M&A deal with Galapagos
Bioworld-13h ago-1 sources
China’s pharma rise rattles US policymakersScience
China’s pharma rise rattles US policymakers
Bioworld-13h ago-1 sources